Ron Squarer, Chief Executive of Array BioPharma (NASDAQ: ARRY), sits down with PropThink.com to discuss the company’s pipeline, positioning, and commercialization strategies. Squarer says robust partnerships are representative of the quality of Array’s science; the company has 14 compounds under development with 10 in Phase II studies. He goes on to talk about moving three products into late-stage trials and the importance of strategic partners in AstraZeneca (NYSE: AZN), Novartis (NYSE: NVS), Roche (OTCQX: RHHBY) and Amgen (NASDAQ: AMGN). Array plans on partnering more of its products according to Squarer, who says the company has historically been able to negotiate deals with large upfront, milestone, and royalty payments. Array BioPharma’s Chief Executive also provides insight into some of the catalysts for this year and some moving forward.